Quantcast

Latest nausea Stories

2010-04-12 13:47:38

It's not uncommon for individuals to take as many as a dozen different prescriptions, each with its own set of possible side effects. If a patient experiences one of the potential hundreds of different adverse reactions such as nausea, headaches, insomnia or heart palpitations, how does the physician quickly and accurately determine which drug is the culprit? Jon D. Duke, M.D., a medical informatics fellow at the Regenstrief Institute and the Indiana University School of Medicine, has created...

2010-04-08 07:00:00

BRIDGEWATER, N.J., April 8 /PRNewswire/ -- Migraineurs and the physicians who treat them will soon have a new option for the acute treatment of migraine. Study results published in Cephalalgia, the international journal of headache, demonstrate that CAMBIA(TM) (diclofenac potassium for oral solution) reduces migraine pain within 30 minutes. The results of the International Migraine Pain Assessment Clinical Trial (IMPACT) showed clinically significant improvement following treatment with...

2010-04-05 09:09:15

People with severe stomach disorders can sometimes suffer from chronic vomiting. This symptom can be treated with electrical impulses from a pacemaker in the stomach. A new method enables patients who could benefit from this treatment to be identified, and electrical stimulation leads to reduced nausea and fewer days in hospital, shows a study from the Sahlgrenska Academy at the University of Gothenburg, Sweden. Gastric electrical stimulation has previously been shown to be effective in most...

2010-03-01 08:06:46

Bone marrow transplant patients say two of the most debilitating side effects of the treatment are nausea and vomiting caused by chemotherapy and radiation. But a Loyola University Health System study has found the drug aprepitant can dramatically reduce both nausea and vomiting when combined with other anti-nausea drugs. Seventy-three percent of patients receiving aprepitant experienced no vomiting during the study period, compared with 23 percent of patients who received a placebo. (Both...

2010-02-22 06:00:00

SAN FRANCISCO, Feb. 22 /PRNewswire/ -- At the 17th Conference on Retroviruses and Opportunistic Infections (CROI), ViiV Healthcare presented new data across its broad range of investigational and current medicines for the treatment of HIV/AIDS. Highlighted data at the conference included an oral presentation on the investigational integrase inhibitor, S/GSK1349572, as well as data presentations on SELZENTRY® (maraviroc) and EPZICOM®...

2010-02-17 15:10:00

SAN FRANCISCO, Feb. 17 /PRNewswire/ -- In a new study of treatment-experienced HIV-1-infected adults with no PREZISTA® (darunavir) resistance-associated mutations (RAMs), 72 percent of patients in the PREZISTA/ritonavir (r) (800/100 mg) once-daily arm achieved undetectable viral loads (<50 copies/mL) compared with 71 percent of patients in the PREZISTA/r (600/100 mg) twice-daily arm. The study met its primary objective of non-inferiority. These data from the Phase 3b...

2010-01-29 16:31:00

RESEARCH TRIANGLE PARK, N.C., Jan. 29 /PRNewswire-FirstCall/ -- GlaxoSmithKline (NYSE: GSK) announced today that the U.S. Food and Drug Administration has approved Lamictal®XR(TM) (lamotrigine) Extended-Release Tablets as once-a-day, add-on therapy for epilepsy in patients ages 13 years and older with primary generalized tonic-clonic seizures. This is an expanded label, as Lamictal XR is approved for partial onset seizures (with or without secondary generalization) for...

2010-01-28 07:30:00

BRIDGEWATER, N.J., Jan. 27 /PRNewswire/ -- Tibotec Therapeutics announced today that the U.S. Food and Drug Administration (FDA) has approved a labeling update for PREZISTA® (darunavir) tablets to include 96-week data from the ARTEMIS and TITAN studies. Both ARTEMIS and TITAN evaluated the efficacy and safety of PREZISTA with ritonavir (r) vs. lopinavir/r in combination with other antiretrovirals (ARVs) for the treatment of human immunodeficiency virus (HIV-1) in...

2009-12-10 16:00:00

WILMINGTON, Del., Dec. 10 /PRNewswire-FirstCall/ -- AstraZeneca (NYSE: AZN) today announced that data from a Phase III study of postmenopausal women with hormone receptor-positive advanced breast cancer presented at the San Antonio Breast Cancer Symposium (Abstract 25) showed treatment with fulvestrant (FASLODEX) 500 mg reduced the risk of disease progression (assessed as time to progression (TTP)) by 20% (HR 0.80; 95% CI 0.68-0.94, p=0.006) when compared with fulvestrant 250 mg, the dose...

2009-12-04 10:00:00

American Journal of Cardiology paper sheds light on heart attack symptoms DALLAS, Dec. 4 /PRNewswire-USNewswire/ -- Researchers at Texas Health Presbyterian Hospital Dallas are investigating what symptoms could help doctors better spot heart attacks and if certain symptoms might indicate different types of heart attacks. Their most recent work, "Relation of Nausea and Vomiting in Acute Myocardial Infarction to Location of the Infarct," appears in the December edition of the American...


Word of the Day
snash
  • To talk saucily.
  • Insolent, opprobrious language; impertinent abuse.
This word is Scots in origin and probably imitative.